Table 6.
Class | Entity | Precision | Recall | F-measure |
---|---|---|---|---|
Nanomedicine description | Company | 0.96 | 0.46 | 0.62 |
FDA approval date | 0.97 | 1 | 0.98 | |
Trade name | 0.99 | 1 | 1 | |
US patent | 1 | 1 | 1 | |
Physicochemical characterization | Active ingredient | 0.89 | 0.79 | 0.84 |
Molecular weight | 0.89 | 0.69 | 0.78 | |
Nanoparticle | 0.64 | 0.42 | 0.51 | |
Particle diameter | 1 | 0.71 | 0.83 | |
Surface coating | 0.48 | 0.27 | 0.34 | |
Pharmacokinetic parameters | AUC | 0.82 | 0.47 | 0.60 |
Clearance | 0.74 | 0.65 | 0.69 | |
Cmax | 0.91 | 0.63 | 0.74 | |
Elimination half-life | 0.80 | 0.73 | 0.76 | |
Plasma half-life | 1 | 0.75 | 0.86 | |
Tmax | 0.91 | 0.56 | 0.69 | |
Volume of distribution | 0.91 | 0.87 | 0.89 | |
Exposure | Dose | 0.86 | 0.32 | 0.46 |
Route of administration | 0.95 | 0.49 | 0.65 | |
Biologic response | Adverse reaction | 0.96 | 0.06 | 0.11 |
Indication | 0.98 | 0.53 | 0.69 | |
Total | 0.95 | 0.55 | 0.69 |
Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured in blood; FDA, US Food and Drug Administration; Tmax, time to reach Cmax.